Aster DM Healthcare Limited has informed the Exchange about Competition Commission of India approval
ASTERDM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aster DM Healthcare has received approval from the Competition Commission of India (CCI) on April 15, 2025 for its proposed acquisition and merger with Quality Care India Limited (QCIL). The transaction involves acquiring 1.90 crore equity shares of QCIL from BCP Asia II TopCo IV Pte. Ltd and Centella Mauritius Holdings Limited, through a share swap of 1.86 crore Aster DM equity shares issued on a preferential basis. Additionally, a scheme of amalgamation has been proposed for QCIL to merge into Aster DM Healthcare. This is a key regulatory milestone; the detailed CCI order is still awaited, and other approvals (including shareholder and NCLT) are still pending.
This is a positive step forward for the previously announced QCIL acquisition and merger, removing a major regulatory hurdle. Shareholders should watch for the share exchange ratio, NCLT and shareholder approvals, and any potential dilution from the preferential share issuance.